New drug for sleep apnea brings promising advances in treatment

A obstructive sleep apnea is a chronic condition that affects breathing during sleep, causing repeated pauses in air intake. It is estimated that more than 1 billion people in the world live with this disorder, and many patients do not tolerate the main treatment available: the CPAP (continuous positive pressure device).

But that could be about to change. A new drug for apnea, already approved in the United States, has demonstrated significant clinical results, paving the way for a effective and less invasive drug approach.

What is the new remedy for sleep apnea?

The featured drug is tirzepatide, This substance is already known for treating type 2 diabetes and obesity, but has now also been shown to be effective in controlling sleep apnea in overweight people.

According to a clinical study published in New England Journal of Medicine, tirzepatida was able to reduce the number of respiratory events per hour by up to 63%, an index called AHI (apnea-hypopnea index).

How does apnea medication work in the body?

Tirzepatide acts via the significant weight loss and also by mechanisms that influence respiratory control during sleep. Obesity is one of the main risk factors for sleep apnea, and reducing weight can improve ventilation and reduce airway obstructions.

Moreover, the treatment was effective even in people who did not use CPAP, This will extend access to those who are unable to buy the device.

Benefits observed in clinical trials

The phase 3 clinical trial, called SURMOUNT-OSA, evaluated 469 participants and presented the following results:

• Average reduction of 30 apnea events per hour
• Improved sleep quality
• Significant drop in daytime sleepiness and fatigue
• Almost total remission of apnea in up to 51% of cases

These figures were released by Eli Lilly laboratory, responsible for the research.

When will the apnea medicine be available in Brazil?

In the United States FDA (American regulatory agency) has already approved the use of tirzepatida for the treatment of apnea associated with obesity. In Brazil, the drug is approved by Anvisa for diabetes, but the new indication for apnea has not yet been released.

It is therefore hoped that, with the publication of the results and the growing demand for alternative treatments to CPAP, approval will occur in the next few years.

Other therapies under development

In addition to tirzepatide, another drug called AD109, from the company Apnimed, is also at an advanced stage of study. It acts directly on upper airway muscles, with the potential to be the first specific oral remedy for sleep apnea.

To follow the progress of this treatment, go to the official Apnimed.

A new era in the treatment of sleep apnea

The arrival of drugs such as tirzepatide and AD109 marks a turning point in the treatment of sleep apnea. With robust results and the promise of more comfort and practicality for the patient, the trend is for the drug treatment complements or even replaces CPAP in some cases.

While approval in Brazil is pending, it is important to keep up with your doctor and discuss all the options available.